Keyword: Pharmaceutical

151 results found
Have your say: What’s the best approach to national pharmacare?

After having a chance to digest the parliamentary budget officer’s report projecting that a universal pharmacare program could represent $4.2 billion in savings for Canada, some believe it’s time to end the debate and take action. Elizabeth Kwan, a senior researcher at the Canadian Labour Congress, certainly believes so. “We need an all-out, all-Canadian effort to put […]

Panel orders Soliris price cut but rejects CLHIA bid to reimburse private payers

While a Patented Medicine Prices Review Board hearing panel has ordered Alexion Pharmaceuticals Inc. to lower the price of the drug Soliris, it has rejected a bid by the Canadian Life and Health Insurance Association to make the company reimburse private payers for the overcharges. “Employers have borne the brunt of the overly high pricing, so […]

  • By: Glenn Kauth
  • October 2, 2017 September 13, 2019
  • 08:47
Sun Life to look at effectiveness of pharmacogenetics on plan members

Sun Life Financial will be offering plan members on short- and long-term disability leave for depression or anxiety the chance to take part in a study on the impact of pharmacogenetic testing. The insurer is participating in a study that examines the effectiveness of the technology in partnership with the Centre for Addiction and Mental […]

  • By: Jann Lee
  • August 25, 2017 September 13, 2019
  • 09:30
Ontario joins Alberta, New Brunswick in making abortion pill available for free

Ontario is joining Alberta and New Brunswick in making abortion pill Mifegymiso available at no cost to the public. The abortion pill first became available in Canada in January 2017 at a cost of about $300. This spring, the common drug review recommended public drug coverage for Mifegymiso. “We continue to make important progress helping women across […]

New drug price deal ends Quebec drug tendering plans

Quebec has reached an agreement with the Canadian Generic Pharmaceutical Association to lower drug costs by $1.5 billion over five years, thereby putting an end to the province’s plans to issue tenders for generic drugs. The new agreement will take effect on Oct. 1, 2017, with costs savings coming from price discounts and the launch […]

  • By: Jann Lee
  • July 17, 2017 September 13, 2019
  • 11:32
Green Shield to introduce new pharmacy rating system

Green Shield Canada is rolling out a new pharmacy rating system in October 2017. The insurer’s program will measure individual pharmacies’ performance and provide feedback to help them gain insight into what they’re already doing well and areas where there’s room for improvement, according to a news release. Green Shield will supply all pharmacies across the […]

  • By: Staff
  • July 14, 2017 September 13, 2019
  • 08:00
Drugs costs, genetic testing on agenda for new CLHIA president

As technology and heightened customer expectations spur demand for change in life and health benefits, the Canadian Life and Health Insurance Association is aiming to be “proactive and lead the discussion” on significant issues facing the industry, according to its new president and chief executive officer. There are many questions about big data, says Stephen Frank, […]

  • By: Jann Lee
  • July 5, 2017 September 13, 2019
  • 09:30
Generic industry asks Quebec to abandon ‘risky path’ on drug tenders

The Canadian Generic Pharmaceutical Association is urging Quebec to abandon its plan to issue tenders for generic drugs. The provincial government’s plan represents a risky tendering scheme that could have negative repercussions for the pharmaceutical industry by threatening the supply of generic drugs and indirectly harming the economy, according to a statement by association president Jim […]

  • By: Staff
  • June 29, 2017 September 13, 2019
  • 10:23
Quebec move on drug bids ‘one to watch’ as private plans expected to benefit

Quebec’s long-awaited move to ask drug manufacturers to bid for exclusive supply contracts for generic prescription drugs should help private benefit plans, according to an expert on drug pricing. “I expect private plans to benefit [from this move],” says John-Paul Dowson, managing director at Roubaix Strategies Inc. That’s because, according to Dowson, Quebec law prevents selling drugs […]

  • By: Jann Lee
  • June 28, 2017 September 13, 2019
  • 10:30
Reformulary Group launches early warning system for high-cost drugs

The Reformulary Group has introduced an early warning system that aims to help plan administrators and employers monitor and prepare for new-high cost drugs. The system evaluates new high-cost prescription drugs entering the marketplace and forecasts the expected impact of those drugs to insurance carriers, third-party administrators and employers. Read: Public drug plans’ medication spending […]

  • By: Staff
  • June 26, 2017 September 13, 2019
  • 08:55